# A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

Source: https://onco.cc/trials/nct07691489/  
OnCo record `nct07691489` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Memorial Sloan Kettering Cancer Center, not yet recruiting.

## Summary

A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer is a phase 2, interventional study registered as NCT07691489 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 27 participants, started 2026-08 and due to reach its primary completion in 2029-06. Interventions recorded: Fam-Trastuzumab Deruxtecan-Nxki. Conditions listed: Colorectal Cancer; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum. Primary outcome: Overall Response Rate (ORR). Colorectal eligibility wording from the registry: "* Have histologically confirmed adenocarcinoma of the colon or rectum that is metastatic and/or unresectable". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07691489
- Phase: 2
- Setting: A Phase 2 Trial of Trastuzumab Deruxtecan in Combination With Cetuximab in HER2-low Metastatic Colorectal Cancer That Has Progressed on Standard Therapies
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT07691489: https://clinicaltrials.gov/study/NCT07691489

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [HER2-amplified colorectal cancer](https://onco.cc/cancers/her2-amplified-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07691489.json